Developer docs
API playgroundTry for free, no card

Search company profiles

Domainex

Full company profile

uuid0003yfk

Namestring
Domainex
Legal namestring
Domainex Limited
Websiteurl
domainex.co.uk
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Domainex Limited is a UK-based, privately held Contract Research Organization (CRO) founded in 2001 and headquartered at Chesterford Research Park near Cambridge, providing fully integrated small-molecule drug discovery services to pharmaceutical companies, biotechnology firms, and academic research groups globally. Its service portfolio spans the full pre-clinical continuum — target validation, hit identification, hit-to-lead, lead optimisation, and pre-clinical candidate nomination — across target classes including GPCRs, ion channels, kinases, methyltransferases, proteases, and protein-protein interactions, with therapeutic area focus in oncology, inflammation, CNS, and anti-infectives.

The company is differentiated by a set of proprietary technology platforms: PureDisc™ (a polymer-encapsulated nanodisc approach for stabilising membrane proteins in native lipid environments), LeadBuilder (a virtual screening platform for hit identification), Combinatorial Domain Hunting / CDH (a patented method for expressing difficult protein targets as soluble fragments), and Direct-to-Biology / D2B (an accelerated protein-to-assay workflow). These are complemented by biophysical capabilities such as Spectral Shift, MST, Cryo-EM, and X-ray crystallography. Domainex also recently added biotherapeutics expression and RNA services, and in 2024 became the first CRO to install Nuclera's eProtein Discovery benchtop system.

Domainex generates revenue through fee-for-service contract research engagements priced on a project-by-project basis, using a direct enterprise field-sales model with personalised, collaborative engagement. The customer base is segmented horizontally across large pharma, emerging biotech, and academic translational groups. Indirect signals of commercial traction include an 80% repeat-customer rate, a 95% customer recommendation rate, multiple peer-reviewed publications in high-impact journals (including Nature Communications), named inventors on numerous patents, and collaborations on Wellcome Trust-funded programmes progressing to pre-clinical candidate nomination.

Short descriptiontext

Domainex is a UK-based, privately held integrated drug discovery CRO providing small-molecule services from target validation to pre-clinical candidate nomination to pharma, biotech, and academic clients, anchored by proprietary platforms PureDisc, LeadBuilder, and Combinatorial Domain Hunting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSaffron Walden, United Kingdom
HQ citystring
Saffron Walden
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery CRO, medicinal chemistry services, preclinical research services, biophysical assay services, contract research organization
Industry1 code
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Drug Discovery CRO Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Domainex provides fee-for-service drug discovery research services on a contract basis, offering integrated capabilities from target identification through to pre-clinical candidate nomination. Services are delivered to pharmaceutical companies, biotechnology firms, and academic groups globally on a project-by-project basis, with expertise across multiple therapeutic areas and target classes.

domainex.co.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Domainex is a contract research organization that provides fully integrated small-molecule drug discovery services for pharmaceutical, biotechnology, and academic clients worldwide. Its core service covers the entire pre-clinical pipeline from target validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination, supported by proprietary platforms for membrane protein production, virtual screening, and difficult-target expression.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Reduced drug discovery timelines by up to 30% compared to industry averages through integrated service model
+5 more records
Product overview1 text field

Domainex is an integrated drug discovery CRO providing comprehensive small-molecule drug discovery services from target validation to preclinical candidate nomination. The company's service portfolio centers on proprietary technology platforms including PureDisc™ for membrane protein production, LeadBuilder for virtual screening, Combinatorial Domain Hunting for difficult targets, and Direct-to-Biology for accelerated hit finding. These core technologies are deployed across integrated service offerings spanning biosciences (assay development, biochemistry, cellular biology, biophysics, structural biology including Cryo-EM and X-ray crystallography), medicinal and synthetic chemistry, computational chemistry, fragment-based and high-throughput screening, ADME/DMPK services, and dedicated expertise in target classes such as GPCRs, ion channels, kinases, proteases, and protein-protein interactions. The company operates across therapeutic areas including oncology, inflammation, CNS, and anti-infectives.

Product and service6 records
1Integrated Drug Discovery Services
CategoryIntegrated drug discovery CRO service
Description

End-to-end small-molecule drug discovery service for pharmaceutical, biotechnology, and academic clients, covering the full pre-clinical pipeline from target validation through to pre-clinical candidate nomination, delivered by an in-house multidisciplinary team.

2PureDisc™ Enabled Membrane Protein Production
CategoryMembrane protein production service
Description

Detergent-free membrane protein production service using polymer-encapsulated nanodiscs (PoLiPa) to purify and stabilize membrane proteins — including GPCRs, ion channels, and solute carriers — in their natural lipid composition for biochemical, biophysical, and structural studies.

3LeadBuilder Virtual Screening
CategoryVirtual screening / hit identification service
Description

Proprietary virtual screening service platform that enables rapid and cost-effective access to high-quality chemical hits for hit identification and lead generation, particularly suited for translational research and emerging biotech programs.

4Combinatorial Domain Hunting (CDH)
CategoryProtein expression service
Description

Patented protein expression service for difficult-to-express targets that identifies soluble protein fragments suitable for structural biology, biophysics, and bioassay applications.

5Direct-to-Biology (D2B)
CategoryAccelerated hit-finding service
Description

Accelerated hit-finding service that progresses from gene to assay-ready protein without traditional purification steps, enabling faster iteration in lead discovery programs.

6Spectral Shift and MST Services
CategoryBiophysical screening service
Description

Biophysical screening service that measures ligand-biomolecule interactions directly in solution using Spectral Shift, MicroScale Thermophoresis (MST), and Temperature Related Intensity Change (TRIC) technologies — enabling direct binding measurement, fragment screening, and KD determination from nanomolar to millimolar affinities.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-27
Description

Domainex and Pharmacelera entered a strategic collaboration to accelerate drug discovery for transmembrane proteins such as GPCRs and ion channels. The partnership combines Domainex's stabilisation and high-throughput platforms with Pharmacelera's AI-driven molecular modelling tools to address key therapeutic targets that pose significant development challenges.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-08
Description

Domainex became the first CRO to install Nuclera's eProtein Discovery benchtop system, enabling accelerated integration of antibody expression and binding validation capabilities. This installation marks Domainex's first CRO implementation of the eProtein Discovery technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-04-17
Description

Longstanding collaboration between Domainex and Queen’s University Belfast to discover and develop first-in-class small molecule inhibitors of the FLIP-FADD protein-protein interaction for treatment of non-small cell lung carcinoma. The partnership received Wellcome Trust Seeding Drug Discovery funding and progressed to clinical candidate nomination stage.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration combining QIMR Berghofer's expertise in KMT biology with Domainex's medicinal chemistry, biochemistry, biophysics, and structural biology capabilities to further characterize G9a lysine methyltransferase inhibitor leads for cancer treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Professor Terry Rabbitts' group at Oxford University to develop fragment hits into lead molecules binding to activated RAS and inhibiting RAS-effector protein interactions for cancer treatment. This work resulted in the first published study of structure-based design of direct RAS-effector inhibitors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with St George's University London and University of Manchester on a drug discovery program targeting Der p 1 protease for allergic asthma treatment. The program ultimately led to successful nomination of a candidate drug for inhaled asthma treatment, funded by the Wellcome Trust.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Professor Fred Perino at Wake Forest Medical School demonstrating that DMXD-011 reduced expression of Interferon Stimulated Genes in TREX-1 D18N mutant mice model of familial chilblain lupus, supporting the pre-clinical candidate's disease-modifying potential.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Marjan Versnel at Erasmus University Rotterdam for ex vivo human studies examining the effect of DMXD-011 on cytokine levels in blood samples from patients with SLE, Sjogren's syndrome, and systemic sclerosis.

Peers10 records
TypeDirect peer
Description

China-headquartered global CRO/CDMO offering fully integrated drug discovery and development services including chemistry, biology, DMPK, and pre-clinical capabilities. Direct competitor for biotech and pharma outsourcing with broader scale and lower-cost positioning.

TypeBroad incumbent
Description

Global CRO/CDMO providing fully integrated drug discovery and development services across all major modalities. The dominant Asia-headquartered scale competitor in integrated discovery outsourcing, competing with Domainex primarily on large-pharma accounts and scale-driven pricing.

TypeBroad incumbent
Description

Division of Eurofins Scientific offering integrated drug discovery services including in vitro ADME, pharmacology, medicinal chemistry, and bioanalysis. Significantly larger scale competitor operating globally across multiple discovery and development service lines.

TypeBroad incumbent
Description

Global public CRO offering drug discovery and development services across multiple modalities and target classes. The dominant full-service incumbent that competes with Domainex for large-pharma integrated discovery contracts, with substantially greater scale and global footprint.

TypeDirect peer
Description

US-based CRO providing drug discovery services including biochemical and cell-based assay services, medicinal chemistry, and biophysics. Comparable in scope to Domainex's biology and screening services with strong overlap in biochemical assay offerings.

TypeDirect peer
Description

UK-based CRO providing drug discovery and analytical services including medicinal chemistry, in vitro pharmacology, and ADME. Comparable mid-sized UK CRO competing for the same European biotech and academic clients as Domainex.

TypeBroad incumbent
Description

Large publicly-listed German integrated drug discovery CRO offering end-to-end services from target identification through pre-clinical and beyond. Operates at significantly larger scale than Domainex across multiple sites globally and represents the broad incumbent benchmark in integrated discovery outsourcing.

TypeDirect peer
Description

Scotland-based integrated drug discovery CRO offering medicinal chemistry, biology, and DMPK services with similar size and target client base to Domainex. Provides a directly comparable UK/European mid-sized CRO alternative.

TypeDirect peer
Description

Poland-headquartered CRO offering integrated drug discovery services spanning medicinal chemistry, in vitro biology, DMPK, and computational chemistry. Comparable mid-sized CRO with strong focus on small-molecule discovery services for biotech and pharma clients.

TypeDirect peer
Description

UK-based integrated drug discovery CRO offering medicinal chemistry, biosciences, and DMPK services to pharma and biotech. Closely comparable to Domainex in size, geography (Nottingham, UK), and integrated service model; competes head-to-head for the same biotech and mid-pharma clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Domainex

Drug Discovery CRO Servicesdomainex.co.uk

Domainex is a UK-based, privately held integrated drug discovery CRO providing small-molecule services from target validation to pre-clinical candidate nomination to pharma, biotech, and academic clients, anchored by proprietary platforms PureDisc, LeadBuilder, and Combinatorial Domain Hunting.

What Domainex does

Domainex Limited is a UK-based, privately held Contract Research Organization (CRO) founded in 2001 and headquartered at Chesterford Research Park near Cambridge, providing fully integrated small-molecule drug discovery services to pharmaceutical companies, biotechnology firms, and academic research groups globally. Its service portfolio spans the full pre-clinical continuum — target validation, hit identification, hit-to-lead, lead optimisation, and pre-clinical candidate nomination — across target classes including GPCRs, ion channels, kinases, methyltransferases, proteases, and protein-protein interactions, with therapeutic area focus in oncology, inflammation, CNS, and anti-infectives.

The company is differentiated by a set of proprietary technology platforms: PureDisc™ (a polymer-encapsulated nanodisc approach for stabilising membrane proteins in native lipid environments), LeadBuilder (a virtual screening platform for hit identification), Combinatorial Domain Hunting / CDH (a patented method for expressing difficult protein targets as soluble fragments), and Direct-to-Biology / D2B (an accelerated protein-to-assay workflow). These are complemented by biophysical capabilities such as Spectral Shift, MST, Cryo-EM, and X-ray crystallography. Domainex also recently added biotherapeutics expression and RNA services, and in 2024 became the first CRO to install Nuclera's eProtein Discovery benchtop system.

Domainex generates revenue through fee-for-service contract research engagements priced on a project-by-project basis, using a direct enterprise field-sales model with personalised, collaborative engagement. The customer base is segmented horizontally across large pharma, emerging biotech, and academic translational groups. Indirect signals of commercial traction include an 80% repeat-customer rate, a 95% customer recommendation rate, multiple peer-reviewed publications in high-impact journals (including Nature Communications), named inventors on numerous patents, and collaborations on Wellcome Trust-funded programmes progressing to pre-clinical candidate nomination.

Domainex firmographics

Firmographics
Name
Domainex
Legal name
Domainex Limited
Website
https://domainex.co.uk
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Domainex is a UK-based, privately held integrated drug discovery CRO providing small-molecule services from target validation to pre-clinical candidate nomination to pharma, biotech, and academic clients, anchored by proprietary platforms PureDisc, LeadBuilder, and Combinatorial Domain Hunting.
Ownership category
akta.pro rank

Domainex industry classification

Industry
Product category
Drug Discovery CRO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Keywords

  • Drug discovery CRO
  • Medicinal chemistry services
  • Preclinical research services
  • Biophysical assay services
  • Contract research organization

Where Domainex is headquartered

Location

Headquarters

HQ city
Saffron Walden
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Domainex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Domainex provides fee-for-service drug discovery research services on a contract basis, offering integrated capabilities from target identification through to pre-clinical candidate nomination. Services are delivered to pharmaceutical companies, biotechnology firms, and academic groups globally on a project-by-project basis, with expertise across multiple therapeutic areas and target classes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Domainex product offering

Product offering

Core offering

Domainex is a contract research organization that provides fully integrated small-molecule drug discovery services for pharmaceutical, biotechnology, and academic clients worldwide. Its core service covers the entire pre-clinical pipeline from target validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination, supported by proprietary platforms for membrane protein production, virtual screening, and difficult-target expression.

Product overview

Domainex is an integrated drug discovery CRO providing comprehensive small-molecule drug discovery services from target validation to preclinical candidate nomination. The company's service portfolio centers on proprietary technology platforms including PureDisc™ for membrane protein production, LeadBuilder for virtual screening, Combinatorial Domain Hunting for difficult targets, and Direct-to-Biology for accelerated hit finding. These core technologies are deployed across integrated service offerings spanning biosciences (assay development, biochemistry, cellular biology, biophysics, structural biology including Cryo-EM and X-ray crystallography), medicinal and synthetic chemistry, computational chemistry, fragment-based and high-throughput screening, ADME/DMPK services, and dedicated expertise in target classes such as GPCRs, ion channels, kinases, proteases, and protein-protein interactions. The company operates across therapeutic areas including oncology, inflammation, CNS, and anti-infectives.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Drug Discovery Services End-to-end small-molecule drug discovery service for pharmaceutical, biotechnology, and academic clients, covering the full pre-clinical pipeline from target validation through to pre-clinical candidate nomination, delivered by an in-house multidisciplinary team.
  • PureDisc™ Enabled Membrane Protein Production Detergent-free membrane protein production service using polymer-encapsulated nanodiscs (PoLiPa) to purify and stabilize membrane proteins — including GPCRs, ion channels, and solute carriers — in their natural lipid composition for biochemical, biophysical, and structural studies.
  • LeadBuilder Virtual Screening Proprietary virtual screening service platform that enables rapid and cost-effective access to high-quality chemical hits for hit identification and lead generation, particularly suited for translational research and emerging biotech programs.
  • Combinatorial Domain Hunting (CDH) Patented protein expression service for difficult-to-express targets that identifies soluble protein fragments suitable for structural biology, biophysics, and bioassay applications.
  • Direct-to-Biology (D2B) Accelerated hit-finding service that progresses from gene to assay-ready protein without traditional purification steps, enabling faster iteration in lead discovery programs.
  • Spectral Shift and MST Services Biophysical screening service that measures ligand-biomolecule interactions directly in solution using Spectral Shift, MicroScale Thermophoresis (MST), and Temperature Related Intensity Change (TRIC) technologies — enabling direct binding measurement, fragment screening, and KD determination from nanomolar to millimolar affinities.

Quantifiable outcome

  • Reduced drug discovery timelines by up to 30% compared to industry averages through integrated service model
  • +5 more outcomes

Companies that use Domainex

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Domainex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Domainex partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • PharmaceleracoreStrategic or Co-development Partner · 27 August 2025Domainex and Pharmacelera entered a strategic collaboration to accelerate drug discovery for transmembrane proteins such as GPCRs and ion channels. The partnership combines Domainex's stabilisation and high-throughput platforms with Pharmacelera's AI-driven molecular modelling tools to address key therapeutic targets that pose significant development challenges.
  • NucleracoreTechnology or Integration · 8 November 2024Domainex became the first CRO to install Nuclera's eProtein Discovery benchtop system, enabling accelerated integration of antibody expression and binding validation capabilities. This installation marks Domainex's first CRO implementation of the eProtein Discovery technology.
  • Queen's University BelfastcoreStrategic or Co-development Partner · 17 April 2015Longstanding collaboration between Domainex and Queen’s University Belfast to discover and develop first-in-class small molecule inhibitors of the FLIP-FADD protein-protein interaction for treatment of non-small cell lung carcinoma. The partnership received Wellcome Trust Seeding Drug Discovery funding and progressed to clinical candidate nomination stage.
  • QIMR BerghofercoreStrategic or Co-development PartnerCollaboration combining QIMR Berghofer's expertise in KMT biology with Domainex's medicinal chemistry, biochemistry, biophysics, and structural biology capabilities to further characterize G9a lysine methyltransferase inhibitor leads for cancer treatment.
  • University of OxfordcoreStrategic or Co-development PartnerCollaboration with Professor Terry Rabbitts' group at Oxford University to develop fragment hits into lead molecules binding to activated RAS and inhibiting RAS-effector protein interactions for cancer treatment. This work resulted in the first published study of structure-based design of direct RAS-effector inhibitors.
  • St George's University London and University of ManchestercoreStrategic or Co-development PartnerCollaboration with St George's University London and University of Manchester on a drug discovery program targeting Der p 1 protease for allergic asthma treatment. The program ultimately led to successful nomination of a candidate drug for inhaled asthma treatment, funded by the Wellcome Trust.
  • Wake Forest Medical SchoolminorStrategic or Co-development PartnerCollaboration with Professor Fred Perino at Wake Forest Medical School demonstrating that DMXD-011 reduced expression of Interferon Stimulated Genes in TREX-1 D18N mutant mice model of familial chilblain lupus, supporting the pre-clinical candidate's disease-modifying potential.
  • Erasmus University RotterdamminorStrategic or Co-development PartnerCollaboration with Marjan Versnel at Erasmus University Rotterdam for ex vivo human studies examining the effect of DMXD-011 on cytokine levels in blood samples from patients with SLE, Sjogren's syndrome, and systemic sclerosis.

Scale indicators2 records

Domainex competitors and assessment

Company assessment

Direct peers

  • Pharmaron: China-headquartered global CRO/CDMO offering fully integrated drug discovery and development services including chemistry, biology, DMPK, and pre-clinical capabilities. Direct competitor for biotech and pharma outsourcing with broader scale and lower-cost positioning.
  • Reaction Biology Corp: US-based CRO providing drug discovery services including biochemical and cell-based assay services, medicinal chemistry, and biophysics. Comparable in scope to Domainex's biology and screening services with strong overlap in biochemical assay offerings.
  • Concept Life Sciences: UK-based CRO providing drug discovery and analytical services including medicinal chemistry, in vitro pharmacology, and ADME. Comparable mid-sized UK CRO competing for the same European biotech and academic clients as Domainex.
  • BioAscent Discovery: Scotland-based integrated drug discovery CRO offering medicinal chemistry, biology, and DMPK services with similar size and target client base to Domainex. Provides a directly comparable UK/European mid-sized CRO alternative.
  • Selvita: Poland-headquartered CRO offering integrated drug discovery services spanning medicinal chemistry, in vitro biology, DMPK, and computational chemistry. Comparable mid-sized CRO with strong focus on small-molecule discovery services for biotech and pharma clients.
  • Sygnature Discovery: UK-based integrated drug discovery CRO offering medicinal chemistry, biosciences, and DMPK services to pharma and biotech. Closely comparable to Domainex in size, geography (Nottingham, UK), and integrated service model; competes head-to-head for the same biotech and mid-pharma clients.

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO providing fully integrated drug discovery and development services across all major modalities. The dominant Asia-headquartered scale competitor in integrated discovery outsourcing, competing with Domainex primarily on large-pharma accounts and scale-driven pricing.
  • Eurofins Discovery Services: Division of Eurofins Scientific offering integrated drug discovery services including in vitro ADME, pharmacology, medicinal chemistry, and bioanalysis. Significantly larger scale competitor operating globally across multiple discovery and development service lines.
  • Charles River Laboratories: Global public CRO offering drug discovery and development services across multiple modalities and target classes. The dominant full-service incumbent that competes with Domainex for large-pharma integrated discovery contracts, with substantially greater scale and global footprint.
  • Evotec SE: Large publicly-listed German integrated drug discovery CRO offering end-to-end services from target identification through pre-clinical and beyond. Operates at significantly larger scale than Domainex across multiple sites globally and represents the broad incumbent benchmark in integrated discovery outsourcing.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights6 records

Customer concentration

Domainex social profiles

Digital presence

Domainex compliance and trust

Trust signal

Compliance1 record

Domainex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Domainex leadership team

Management profile

Number of profiles

Profiles9 records

Domainex funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Domainex M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Domainex

What does Domainex do?

Domainex is a contract research organization that provides fully integrated small-molecule drug discovery services for pharmaceutical, biotechnology, and academic clients worldwide. Its core service covers the entire pre-clinical pipeline from target validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination, supported by proprietary platforms for membrane protein production, virtual screening, and difficult-target expression.

Is Domainex a public or private company?

Domainex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Domainex founded?

Domainex was founded in 2001. It employs 51 to 100 people.

Where is Domainex based?

Domainex is headquartered in Saffron Walden, United Kingdom, in the Europe region.

How does Domainex make money?

One revenue line is on record: contract Research Services.

Who are Domainex's main competitors?

Direct peers on record are Pharmaron, Reaction Biology Corp, Concept Life Sciences, BioAscent Discovery, Selvita and Sygnature Discovery. Broad incumbents are WuXi AppTec, Eurofins Discovery Services, Charles River Laboratories and Evotec SE.

Does Domainex have an API?

No public API is recorded for Domainex.

What industry is Domainex in?

Domainex's product category is Drug Discovery CRO Services. Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BBCSisters inspired by death of grandmother develop longevity drugTwo sisters, Dr. Carina Kern and Serena Kern-Libera, founded Cambridge-based biotech company LinkGevity to develop LINK-001, a first-of-its-kind drug that blocks necrosis (unplanned cell death) by targeting specific calcium channels, identified using AI. Independent verification by Domainex showed cell death was blocked for up to 11 days compared to the typical 24-48 hours, with the results attracting funding from Innovate UK, The Francis Crick Institute, and NASA. The Health Innovation Network is supporting LinkGevity in preparing for human clinical trials focusing on acute kidney injury prevention, with an estimated seven million people in the UK suffering from kidney disease which currently has no cure.DatamintelligenceMarket Growth Rate, Industry Insights and Forecast 2024-2031This article presents a market research overview of the global drug discovery outsourcing services market, which was valued at US$ YY million in 2022 and is projected to reach US$ YY million by 2030 with a CAGR of YY% during 2024-2031. Key market drivers include the rise of AI-enabled drug discovery methods, increasing chronic disease prevalence, and expanding biologics market, while high drug development costs and stringent regulatory requirements serve as restraints. The competitive landscape features major providers including ThermoFisher Scientific, Charles River Laboratories International Inc., WuXi AppTec Co.Ltd., Albany Molecular Research Inc., Aragen Life Sciences Ltd, Sygnature Discovery, Pharmaron Beijing Co. Ltd, Domainex Ltd., Jubilant Biosys Ltd., and Evotec, with North America accounting for approximately 38.4% market share in 2022.PharmaceleraDomainex and Pharmacelera Join Forces to Accelerate Discovery of Molecules Targeting Transmembrane ProteinsDomainex, a UK-based integrated drug discovery services company, and Pharmacelera, a Barcelona-based AI molecular modelling company, announced a strategic collaboration on August 27, 2025 to advance drug discovery targeting transmembrane proteins such as GPCRs and ion channels. The partnership combines Domainex's Polymer Lipid Particle (PoLiPa) technology and Direct-to-Biology (D2B) platform with Pharmacelera's AI-driven exaScreen and PharmScreen platforms to overcome the structural challenges of these difficult drug targets. Both companies aim to accelerate the identification and optimisation of novel, high-quality drug candidates against targets that represent over 60% of current drug targets but pose significant discovery challenges.DomainexDomainex and Pharmacelera Join Forces to Accelerate Discovery of Molecules Targeting Transmembrane ProteinsDomainex and Pharmacelera announced a strategic collaboration on August 27, 2025, to jointly support drug discovery programmes targeting transmembrane proteins such as GPCRs and ion channels. The partnership combines Domainex's PoLiPa technology and Direct-to-Biology platform with Pharmacelera's AI-driven exaScreen and PharmScreen molecular modelling platforms. Transmembrane proteins represent over 60% of current drug targets but are difficult to work with due to their structural complexity outside lipid membranes.openPR.comRevolutionizing Healthcare: Drug Discovery Services Market Surges with AI & Precision Medicine Innovations 2025 | Top Key Players - Domainex, Evotec AG, Albany Molecular Research Inc.The global drug discovery services market reached US$15.58 billion in 2023 and is projected to reach US$46.52 billion by 2031, a CAGR of 14.8%. Key players include Domainex, Evotec AG, and Albany Molecular Research Inc., with growth driven by AI and precision medicine innovations.EIN PresswireIschemia Reperfusion Injury Global Market Report 2025: In-Depth Analysis And ForecastThe ischemia reperfusion injury market grew from $1.56 billion in 2024 to $1.68 billion in 2025, a CAGR of 8.1%. It is forecast to reach $2.26 billion by 2029, driven by cardiovascular disease prevalence, organ transplantation demand, and aging population. North America held the largest 2024 share, with Asia-Pacific expected to grow fastest.Cambridge IndependentWho will triumph at the Cambridge Independent SME Cambridgeshire Business Awards 2023?The 2023 Cambridge Independent SME Cambridgeshire Business Awards gala will be held on September 28 at the Cambridge Country Club, with winners announced in categories from Business Innovation to Business Person of the Year. Barr Ellison Law returns as headline sponsor, and finalists will also compete at the National SME Business Awards.DomainexHow do you choose between HTS, virtual screening and FBDD?The article compares three primary drug discovery approaches—High Throughput Screening (HTS), virtual screening, and Fragment-Based Drug Discovery (FBDD)—analyzing their respective methodologies, advantages, and limitations. It highlights that while HTS remains a traditional mainstay, advances in computational design and biophysical techniques have made virtual screening and FBDD viable alternatives with potentially lower costs and faster timelines. The text notes that the optimal strategy is target-dependent and references Domainex's fragment library as an example of adhering to Rule-of-3 criteria.PR NewswireInvivoscribe lanza nueva división dedicada al desarrollo de medicamentos. Obtiene licencia de inhibidores de micromoléculas de Domainex para tratar la leucemia mielógena agudaInvivoscribe, Inc. announced the launch of a fully integrated drug development engine combined with its diagnostic expertise and global clinical testing capabilities. The company also entered into a licensing agreement with Domainex Ltd. to develop and commercialize certain preclinical micromolecule molecules as oral immunotherapy agents for treating hematologic neoplasms, including acute myeloid leukemia. The deal includes an upfront payment, milestone payments tied to development phases, regulatory filing, and commercialization, plus royalties on resulting commercial products.PR NewswireInvivoscribe etabliert neue Sparte für Arzneimittelentwicklung und lizenziert niedermolekulare Inhibitoren von Domainex zur Behandlung der akuten myeloischen LeukämieInvivoscribe, Inc., a precision diagnostics company based in San Diego, announced on July 14, 2020 the establishment of a fully integrated drug development division called Invivoscribe Therapeutics. The company licensed preclinical molecules and related low-molecular weight inhibitors from UK-based Domainex Ltd. for oral immunotherapy to treat hematologic malignancies, including acute myeloid leukemia. The licensing agreement includes an upfront payment, milestone payments tied to development phases, regulatory submissions, and commercialization, as well as royalties on resulting commercial products.